Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Apr;70(4):2431–2439. doi: 10.1128/jvi.70.4.2431-2439.1996

The role of human adenovirus early region 3 proteins (gp19K, 10.4K, 14.5K, and 14.7K) in a murine pneumonia model.

T E Sparer 1, R A Tripp 1, D L Dillehay 1, T W Hermiston 1, W S Wold 1, L R Gooding 1
PMCID: PMC190086  PMID: 8642671

Abstract

Products of human adenovirus (Ad) early region 3 (E3) inhibit both specific (cytotoxic T lymphocytes [CTLs]) and innate (tumor necrosis factor alpha [TNF-alpha]) immune responses in vitro. The E3 gp19K protein prevents CTL recognition of Ad-infected fibroblasts by sequestering major histocompatibility complex class I proteins in the endoplasmic reticulum. E3 proteins 10.4K, 14.5K, and 14.7K function to protect infected cells from TNF-alpha cytolysis. To address the in vivo functions of these proteins, Ad mutants that lack the E3 genes encoding these proteins were inoculated intranasally into C57BL/10SnJ (H-2b) mice. Mutants that lack the gp19K gene failed to alter CTL generation or to affect Ad-induced pulmonary infiltrates. Since gamma interferon (IFN-gamma) is capable of overcoming gp19K suppression of CTL lysis in vitro, mice were depleted of IFN-gamma and inoculated with gp19K mutants. Even when IFN-gamma was depleted, gp19K was incapable of altering pulmonary lesions. These resuls are not in accord with the function of gp19K in vitro and suggest that gp19K does not affect immune recognition in vivo during an acute virus infection, yet they do not exclude the possibility that gp19K blocks immune recognition of Ad during a persistent infection. In contrast, when mice were inoculated with Ad mutants that lack the TNF resistance genes (14.7K and either 10.4K or 14.5K), there was a marked increase in alveolar infiltration and no change in the amounts of perivascular/peribronchiolar infiltration compared with wild-type-Ad-induced pathology. These findings demonstrate the importance of TNF susceptibility and TNF by-products for recruiting inflammatory cells into the lungs during Ad infections.

Full Text

The Full Text of this article is available as a PDF (1.5 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allan W., Tabi Z., Cleary A., Doherty P. C. Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol. 1990 May 15;144(10):3980–3986. [PubMed] [Google Scholar]
  2. Andersson M., Päbo S., Nilsson T., Peterson P. A. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell. 1985 Nov;43(1):215–222. doi: 10.1016/0092-8674(85)90026-1. [DOI] [PubMed] [Google Scholar]
  3. Bevan M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976 May 1;143(5):1283–1288. doi: 10.1084/jem.143.5.1283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bhat B. M., Wold W. S. A small deletion distant from a splice or polyadenylation site dramatically alters pre-mRNA processing in region E3 of adenovirus. J Virol. 1987 Dec;61(12):3938–3945. doi: 10.1128/jvi.61.12.3938-3945.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bhat R. A., Thimmappaya B. Two small RNAs encoded by Epstein-Barr virus can functionally substitute for the virus-associated RNAs in the lytic growth of adenovirus 5. Proc Natl Acad Sci U S A. 1983 Aug;80(15):4789–4793. doi: 10.1073/pnas.80.15.4789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Brady H. A., Scaria A., Wold W. S. Map of cis-acting sequences that determine alternative pre-mRNA processing in the E3 complex transcription unit of adenovirus. J Virol. 1992 Oct;66(10):5914–5923. doi: 10.1128/jvi.66.10.5914-5923.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brady H. A., Wold W. S. Identification of a novel sequence that governs both polyadenylation and alternative splicing in region E3 of adenovirus. Nucleic Acids Res. 1987 Nov 25;15(22):9397–9416. doi: 10.1093/nar/15.22.9397. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Buchmeier N. A., Schreiber R. D. Requirement of endogenous interferon-gamma production for resolution of Listeria monocytogenes infection. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7404–7408. doi: 10.1073/pnas.82.21.7404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burgert H. G., Kvist S. An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens. Cell. 1985 Jul;41(3):987–997. doi: 10.1016/s0092-8674(85)80079-9. [DOI] [PubMed] [Google Scholar]
  10. Buttyan R., Olsson C. A., Pintar J., Chang C., Bandyk M., Ng P. Y., Sawczuk I. S. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol. 1989 Aug;9(8):3473–3481. doi: 10.1128/mcb.9.8.3473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Chang D. J., Ringold G. M., Heller R. A. Cell killing and induction of manganous superoxide dismutase by tumor necrosis factor-alpha is mediated by lipoxygenase metabolites of arachidonic acid. Biochem Biophys Res Commun. 1992 Oct 30;188(2):538–546. doi: 10.1016/0006-291x(92)91089-9. [DOI] [PubMed] [Google Scholar]
  12. Cox J. H., Buller R. M., Bennink J. R., Yewdell J. W., Karupiah G. Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted responses to vaccinia virus. Virology. 1994 Nov 1;204(2):558–562. doi: 10.1006/viro.1994.1569. [DOI] [PubMed] [Google Scholar]
  13. Crystal R. G., McElvaney N. G., Rosenfeld M. A., Chu C. S., Mastrangeli A., Hay J. G., Brody S. L., Jaffe H. A., Eissa N. T., Danel C. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet. 1994 Sep;8(1):42–51. doi: 10.1038/ng0994-42. [DOI] [PubMed] [Google Scholar]
  14. Day D. B., Zachariades N. A., Gooding L. R. Cytolysis of adenovirus-infected murine fibroblasts by IFN-gamma-primed macrophages is TNF- and contact-dependent. Cell Immunol. 1994 Aug;157(1):223–238. doi: 10.1006/cimm.1994.1218. [DOI] [PubMed] [Google Scholar]
  15. Eichelberger M., Allan W., Zijlstra M., Jaenisch R., Doherty P. C. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med. 1991 Oct 1;174(4):875–880. doi: 10.1084/jem.174.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Fox J. P., Hall C. E., Cooney M. K. The Seattle Virus Watch. VII. Observations of adenovirus infections. Am J Epidemiol. 1977 Apr;105(4):362–386. doi: 10.1093/oxfordjournals.aje.a112394. [DOI] [PubMed] [Google Scholar]
  17. Früh K., Ahn K., Djaballah H., Sempé P., van Endert P. M., Tampé R., Peterson P. A., Yang Y. A viral inhibitor of peptide transporters for antigen presentation. Nature. 1995 Jun 1;375(6530):415–418. doi: 10.1038/375415a0. [DOI] [PubMed] [Google Scholar]
  18. Gilead Z., Ginsberg H. S. Comparison of the rates of ultraviolet inactivation of the capacity of type 12 adenovirus to infect cells and to induce T antigen formation. J Bacteriol. 1966 Dec;92(6):1853–1854. doi: 10.1128/jb.92.6.1853-1854.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ginsberg H. S., Horswood R. L., Chanock R. M., Prince G. A. Role of early genes in pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A. 1990 Aug;87(16):6191–6195. doi: 10.1073/pnas.87.16.6191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Ginsberg H. S., Lundholm-Beauchamp U., Horswood R. L., Pernis B., Wold W. S., Chanock R. M., Prince G. A. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci U S A. 1989 May;86(10):3823–3827. doi: 10.1073/pnas.86.10.3823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ginsberg H. S., Moldawer L. L., Sehgal P. B., Redington M., Kilian P. L., Chanock R. M., Prince G. A. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1651–1655. doi: 10.1073/pnas.88.5.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gooding L. R., Edwards C. B. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J Immunol. 1980 Mar;124(3):1258–1262. [PubMed] [Google Scholar]
  23. Gooding L. R., Elmore L. W., Tollefson A. E., Brady H. A., Wold W. S. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumor necrosis factor. Cell. 1988 May 6;53(3):341–346. doi: 10.1016/0092-8674(88)90154-7. [DOI] [PubMed] [Google Scholar]
  24. Gooding L. R., Ranheim T. S., Tollefson A. E., Aquino L., Duerksen-Hughes P., Horton T. M., Wold W. S. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor. J Virol. 1991 Aug;65(8):4114–4123. doi: 10.1128/jvi.65.8.4114-4123.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Gooding L. R. Regulation of TNF-mediated cell death and inflammation by human adenoviruses. Infect Agents Dis. 1994 Apr-Jun;3(2-3):106–115. [PubMed] [Google Scholar]
  26. Gooding L. R., Sofola I. O., Tollefson A. E., Duerksen-Hughes P., Wold W. S. The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis. J Immunol. 1990 Nov 1;145(9):3080–3086. [PubMed] [Google Scholar]
  27. Gooding L. R. Specificities of killing by cytotoxic lymphocytes generated in vivo and in vitro to syngeneic SV40 transformed cells. J Immunol. 1977 Mar;118(3):920–927. [PubMed] [Google Scholar]
  28. Gooding L. R. Virus proteins that counteract host immune defenses. Cell. 1992 Oct 2;71(1):5–7. doi: 10.1016/0092-8674(92)90259-f. [DOI] [PubMed] [Google Scholar]
  29. Green M., Wold W. S. Human adenoviruses: growth, purification, and transfection assay. Methods Enzymol. 1979;58:425–435. doi: 10.1016/s0076-6879(79)58157-9. [DOI] [PubMed] [Google Scholar]
  30. Grunhaus A., Cho S., Horwitz M. S. Association of vaccinia virus-expressed adenovirus E3-19K glycoprotein with class I MHC and its effects on virulence in a murine pneumonia model. Virology. 1994 May 1;200(2):535–546. doi: 10.1006/viro.1994.1216. [DOI] [PubMed] [Google Scholar]
  31. Harris S. L., Frank I., Yee A., Cohen G. H., Eisenberg R. J., Friedman H. M. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J Infect Dis. 1990 Aug;162(2):331–337. doi: 10.1093/infdis/162.2.331. [DOI] [PubMed] [Google Scholar]
  32. Hayakawa M., Ishida N., Takeuchi K., Shibamoto S., Hori T., Oku N., Ito F., Tsujimoto M. Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem. 1993 May 25;268(15):11290–11295. [PubMed] [Google Scholar]
  33. Hermiston T. W., Hellwig R., Hierholzer J. C., Wold W. S. Sequence and functional analysis of the human adenovirus type 7 E3-gp19K protein from 17 clinical isolates. Virology. 1993 Dec;197(2):593–600. doi: 10.1006/viro.1993.1633. [DOI] [PubMed] [Google Scholar]
  34. Hill A., Jugovic P., York I., Russ G., Bennink J., Yewdell J., Ploegh H., Johnson D. Herpes simplex virus turns off the TAP to evade host immunity. Nature. 1995 Jun 1;375(6530):411–415. doi: 10.1038/375411a0. [DOI] [PubMed] [Google Scholar]
  35. Hou S., Doherty P. C. Clearance of Sendai virus by CD8+ T cells requires direct targeting to virus-infected epithelium. Eur J Immunol. 1995 Jan;25(1):111–116. doi: 10.1002/eji.1830250120. [DOI] [PubMed] [Google Scholar]
  36. Hou S., Doherty P. C., Zijlstra M., Jaenisch R., Katz J. M. Delayed clearance of Sendai virus in mice lacking class I MHC-restricted CD8+ T cells. J Immunol. 1992 Aug 15;149(4):1319–1325. [PubMed] [Google Scholar]
  37. Knauer M. F., Longmuir K. J., Yamamoto R. S., Fitzgerald T. P., Granger G. A. Mechanism of human lymphotoxin and tumor necrosis factor induced destruction of cells in vitro: phospholipase activation and deacylation of specific-membrane phospholipids. J Cell Physiol. 1990 Mar;142(3):469–479. doi: 10.1002/jcp.1041420305. [DOI] [PubMed] [Google Scholar]
  38. Krajcsi P., Tollefson A. E., Anderson C. W., Stewart A. R., Carlin C. R., Wold W. S. The E3-10.4K protein of adenovirus is an integral membrane protein that is partially cleaved between Ala22 and Ala23 and has a Ccyt orientation. Virology. 1992 Mar;187(1):131–144. doi: 10.1016/0042-6822(92)90302-6. [DOI] [PubMed] [Google Scholar]
  39. Krajcsi P., Tollefson A. E., Anderson C. W., Wold W. S. The adenovirus E3 14.5-kilodalton protein, which is required for down-regulation of the epidermal growth factor receptor and prevention of tumor necrosis factor cytolysis, is an integral membrane protein oriented with its C terminus in the cytoplasm. J Virol. 1992 Mar;66(3):1665–1673. doi: 10.1128/jvi.66.3.1665-1673.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Körner H., Burgert H. G. Down-regulation of HLA antigens by the adenovirus type 2 E3/19K protein in a T-lymphoma cell line. J Virol. 1994 Mar;68(3):1442–1448. doi: 10.1128/jvi.68.3.1442-1448.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Mestan J., Brockhaus M., Kirchner H., Jacobsen H. Antiviral activity of tumour necrosis factor. Synergism with interferons and induction of oligo-2',5'-adenylate synthetase. J Gen Virol. 1988 Dec;69(Pt 12):3113–3120. doi: 10.1099/0022-1317-69-12-3113. [DOI] [PubMed] [Google Scholar]
  42. Mestan J., Digel W., Mittnacht S., Hillen H., Blohm D., Möller A., Jacobsen H., Kirchner H. Antiviral effects of recombinant tumour necrosis factor in vitro. 1986 Oct 30-Nov 5Nature. 323(6091):816–819. doi: 10.1038/323816a0. [DOI] [PubMed] [Google Scholar]
  43. Openshaw P. J. Flow cytometric analysis of pulmonary lymphocytes from mice infected with respiratory syncytial virus. Clin Exp Immunol. 1989 Feb;75(2):324–328. [PMC free article] [PubMed] [Google Scholar]
  44. Pacini D. L., Dubovi E. J., Clyde W. A., Jr A new animal model for human respiratory tract disease due to adenovirus. J Infect Dis. 1984 Jul;150(1):92–97. doi: 10.1093/infdis/150.1.92. [DOI] [PubMed] [Google Scholar]
  45. Prince G. A., Porter D. D., Jenson A. B., Horswood R. L., Chanock R. M., Ginsberg H. S. Pathogenesis of adenovirus type 5 pneumonia in cotton rats (Sigmodon hispidus). J Virol. 1993 Jan;67(1):101–111. doi: 10.1128/jvi.67.1.101-111.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Pruzanski W., Vadas P. Phospholipase A2--a mediator between proximal and distal effectors of inflammation. Immunol Today. 1991 May;12(5):143–146. doi: 10.1016/S0167-5699(05)80042-8. [DOI] [PubMed] [Google Scholar]
  47. Rawle F. C., Tollefson A. E., Wold W. S., Gooding L. R. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K. J Immunol. 1989 Sep 15;143(6):2031–2037. [PubMed] [Google Scholar]
  48. Rock K. L., Gamble S., Rothstein L. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science. 1990 Aug 24;249(4971):918–921. doi: 10.1126/science.2392683. [DOI] [PubMed] [Google Scholar]
  49. Rock K. L., Rothstein L., Gamble S., Fleischacker C. Characterization of antigen-presenting cells that present exogenous antigens in association with class I MHC molecules. J Immunol. 1993 Jan 15;150(2):438–446. [PubMed] [Google Scholar]
  50. Routes J. M., Cook J. L. Resistance of human cells to the adenovirus E3 effect on class I MHC antigen expression. Implications for antiviral immunity. J Immunol. 1990 Apr 1;144(7):2763–2770. [PubMed] [Google Scholar]
  51. Routes J. M., Metz B. A., Cook J. L. Endogenous expression of E1A in human cells enhances the effect of adenovirus E3 on class I major histocompatibility complex antigen expression. J Virol. 1993 Jun;67(6):3176–3181. doi: 10.1128/jvi.67.6.3176-3181.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Smith G. L. Virus strategies for evasion of the host response to infection. Trends Microbiol. 1994 Mar;2(3):81–88. doi: 10.1016/0966-842x(94)90539-8. [DOI] [PubMed] [Google Scholar]
  53. Spitalny G. L., Havell E. A. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities. J Exp Med. 1984 May 1;159(5):1560–1565. doi: 10.1084/jem.159.5.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Stewart A. R., Tollefson A. E., Krajcsi P., Yei S. P., Wold W. S. The adenovirus E3 10.4K and 14.5K proteins, which function to prevent cytolysis by tumor necrosis factor and to down-regulate the epidermal growth factor receptor, are localized in the plasma membrane. J Virol. 1995 Jan;69(1):172–181. doi: 10.1128/jvi.69.1.172-181.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Suffys P., Beyaert R., De Valck D., Vanhaesebroeck B., Van Roy F., Fiers W. Tumour-necrosis-factor-mediated cytotoxicity is correlated with phospholipase-A2 activity, but not with arachidonic acid release per se. Eur J Biochem. 1991 Jan 30;195(2):465–475. doi: 10.1111/j.1432-1033.1991.tb15727.x. [DOI] [PubMed] [Google Scholar]
  56. Suto R., Srivastava P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science. 1995 Sep 15;269(5230):1585–1588. doi: 10.1126/science.7545313. [DOI] [PubMed] [Google Scholar]
  57. Tollefson A. E., Krajcsi P., Pursley M. H., Gooding L. R., Wold W. S. A 14,500 MW protein is coded by region E3 of group C human adenoviruses. Virology. 1990 Mar;175(1):19–29. doi: 10.1016/0042-6822(90)90182-q. [DOI] [PubMed] [Google Scholar]
  58. Tollefson A. E., Krajcsi P., Yei S. P., Carlin C. R., Wold W. S. A 10,400-molecular-weight membrane protein is coded by region E3 of adenovirus. J Virol. 1990 Feb;64(2):794–801. doi: 10.1128/jvi.64.2.794-801.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Tollefson A. E., Stewart A. R., Yei S. P., Saha S. K., Wold W. S. The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus form a complex and function together to down-regulate the epidermal growth factor receptor. J Virol. 1991 Jun;65(6):3095–3105. doi: 10.1128/jvi.65.6.3095-3105.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Tollefson A. E., Wold W. S. Identification and gene mapping of a 14,700-molecular-weight protein encoded by region E3 of group C adenoviruses. J Virol. 1988 Jan;62(1):33–39. doi: 10.1128/jvi.62.1.33-39.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Tufariello J. M., Cho S., Horwitz M. S. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):10987–10991. doi: 10.1073/pnas.91.23.10987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Tufariello J., Cho S., Horwitz M. S. The adenovirus E3 14.7-kilodalton protein which inhibits cytolysis by tumor necrosis factor increases the virulence of vaccinia virus in a murine pneumonia model. J Virol. 1994 Jan;68(1):453–462. doi: 10.1128/jvi.68.1.453-462.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Welsh M. J., Smith A. E., Zabner J., Rich D. P., Graham S. M., Gregory R. J., Pratt B. M., Moscicki R. A. Cystic fibrosis gene therapy using an adenovirus vector: in vivo safety and efficacy in nasal epithelium. Hum Gene Ther. 1994 Feb;5(2):209–219. doi: 10.1089/hum.1994.5.2-209. [DOI] [PubMed] [Google Scholar]
  64. Wherry J. C., Schreiber R. D., Unanue E. R. Regulation of gamma interferon production by natural killer cells in scid mice: roles of tumor necrosis factor and bacterial stimuli. Infect Immun. 1991 May;59(5):1709–1715. doi: 10.1128/iai.59.5.1709-1715.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Wold W. S., Deutscher S. L., Takemori N., Bhat B. M., Magie S. C. Evidence that AGUAUAUGA and CCAAGAUGA initiate translation in the same mRNA region E3 of adenovirus. Virology. 1986 Jan 15;148(1):168–180. doi: 10.1016/0042-6822(86)90412-5. [DOI] [PubMed] [Google Scholar]
  66. Wold W. S., Hermiston T. W., Tollefson A. E. Adenovirus proteins that subvert host defenses. Trends Microbiol. 1994 Nov;2(11):437–443. doi: 10.1016/0966-842x(94)90801-x. [DOI] [PubMed] [Google Scholar]
  67. Wong G. H., Goeddel D. V. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. 1986 Oct 30-Nov 5Nature. 323(6091):819–822. doi: 10.1038/323819a0. [DOI] [PubMed] [Google Scholar]
  68. York I. A., Roop C., Andrews D. W., Riddell S. R., Graham F. L., Johnson D. C. A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes. Cell. 1994 May 20;77(4):525–535. doi: 10.1016/0092-8674(94)90215-1. [DOI] [PubMed] [Google Scholar]
  69. Zilli D., Voelkel-Johnson C., Skinner T., Laster S. M. The adenovirus E3 region 14.7 kDa protein, heat and sodium arsenite inhibit the TNF-induced release of arachidonic acid. Biochem Biophys Res Commun. 1992 Oct 15;188(1):177–183. doi: 10.1016/0006-291x(92)92366-6. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES